九典制药(300705) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 696,028,386.21, representing a 17.79% increase compared to CNY 590,896,382.47 in the same period last year[6] - Net profit attributable to shareholders was CNY 125,775,709.52, a slight increase of 0.08% from CNY 125,669,473.12 year-on-year[6] - Basic earnings per share decreased by 30.56% to CNY 0.25, compared to CNY 0.36 in the same period last year[6] - Total operating revenue for the current period reached ¥696,028,386.21, an increase of 17.76% compared to ¥590,896,382.47 in the previous period[22] - Net profit for the current period was ¥125,775,709.52, slightly up from ¥125,669,473.12, reflecting a marginal increase of 0.08%[23] - The total comprehensive income for the current period was ¥125,775,709.52, slightly higher than ¥125,669,473.12 in the previous period[24] Cash Flow - The net cash flow from operating activities decreased by 38.15% to CNY 147,303,852.15, down from CNY 238,171,199.76 in the previous year[6] - Cash flow from operating activities generated a net amount of ¥147,303,852.15, down 38.19% from ¥238,171,199.76 in the prior period[26] - Net cash flow from investment activities was -$44.91 million, a decrease from -$126.37 million year-over-year[27] - Total cash inflow from financing activities was $56.78 million, compared to $9.00 million in the previous period[27] - Cash and cash equivalents increased by $153.21 million, up from $108.85 million year-over-year[27] - Cash outflow for investment activities totaled $246.16 million, an increase from $126.42 million year-over-year[27] - Cash outflow for financing activities was $5.96 million, compared to $11.95 million in the previous period[27] - Cash inflow from investment activities amounted to $201.25 million, up from $46,000 in the previous period[27] - Cash paid for the acquisition of fixed assets and intangible assets was $66.16 million, down from $86.42 million year-over-year[27] - Cash received from investment income was $1.25 million, unchanged from the previous period[27] Assets and Liabilities - Total assets increased by 3.43% to CNY 3,488,955,041.56 from CNY 3,373,131,232.71 at the end of the previous year[6] - Current assets totaled CNY 1,676,547,724.08, up from CNY 1,601,774,702.04, indicating an increase of about 4.7%[19] - Cash and cash equivalents rose to CNY 588,329,341.07 from CNY 443,307,337.44, marking a significant increase of approximately 32.7%[17] - The company's accounts receivable decreased to CNY 332,261,404.58 from CNY 350,502,639.39, a decline of about 5.2%[17] - Inventory levels remained stable, with a slight decrease from CNY 367,704,817.24 to CNY 366,528,565.07, a change of approximately -0.3%[17] - Total liabilities decreased from CNY 391,863,535.79 to CNY 294,960,082.37, representing a reduction of about 24.7%[19] - Long-term borrowings increased by 43.61% to CNY 183,696,080.00, attributed to stock repurchase loans and project loans[10] - Long-term borrowings increased to CNY 183,696,080.00 from CNY 127,913,000.00, reflecting a growth of approximately 43.6%[19] - Total liabilities amounted to ¥839,592,801.00, a decrease of 0.96% from ¥846,401,371.85[20] - Total equity attributable to shareholders reached ¥2,649,362,240.56, an increase of 4.83% from ¥2,526,729,860.86[20] Research and Development - The company reported a 54.19% increase in R&D expenses, totaling CNY 63,106,394.07, compared to CNY 40,928,107.97 in the previous year[10] - Research and development expenses increased to ¥63,106,394.07, a rise of 54.36% compared to ¥40,928,107.97 in the previous period[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,861[12] - The company reported a total of 125,061,391 shares with restricted sales at the end of the period, up from 124,305,686 shares at the beginning[15] Other Information - The company experienced a significant increase of 3330.65% in special reserves, amounting to CNY 295,936.61, due to increased safety investment reserves[10] - The company reported a decrease in other income by 72.23%, totaling CNY 6,907,915.13, primarily due to a reduction in government subsidies received[10] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[16]